<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04794101</url>
  </required_header>
  <id_info>
    <org_study_id>MGT-RPGR-022</org_study_id>
    <nct_id>NCT04794101</nct_id>
  </id_info>
  <brief_title>Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene</brief_title>
  <official_title>Follow-up Phase 3 Randomized, Controlled Study of AAV5-RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MeiraGTx UK II Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MeiraGTx UK II Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial of AAV5-RPGR vector for patients with X-linked retinitis pigmentosa (XLRP)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">July 5, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>66 Patients randomised in MGT-RPGR-021. 44 patients randomised to Immediate treatment arm. 22 patients randomised to the deferred arm. These patients will be treated in MGT-RPGR-022. All patients to be followed for 60 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in retinal sensitivity as measured by perimetry</measure>
    <time_frame>Month 60</time_frame>
    <description>Change from baseline in retinal sensitivity as measured by perimetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in visual function as measured by Early Treatment of Diabetic Retinopathy Study (ETDRS)</measure>
    <time_frame>Day 0 - Month 60</time_frame>
    <description>Change from baseline in visual function as measured by Early Treatment of Diabetic Retinopathy Study (ETDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in functional vision Change from baseline in functional vision as measured by visual mobility assessment</measure>
    <time_frame>Day 0 - Month 60</time_frame>
    <description>To assess changes in functional vision Change from baseline in functional vision as measured by visual mobility assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes from baseline in patient-reported functional vision as assessed by the patient-reported outcome questionnaire, Impact of Vision Impairment (IVI) - 'Reading and Accessing Information' domain</measure>
    <time_frame>Day 0 - Month 60</time_frame>
    <description>To assess changes from baseline in patient-reported functional vision as assessed by the patient-reported outcome questionnaire, Impact of Vision Impairment (IVI) - 'Reading and Accessing Information' domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in visual function: Contrast sensitivity by Pelli-Robson chart in LogMAR over time through Month 60</measure>
    <time_frame>Through Month 60</time_frame>
    <description>Contrast sensitivity by Pelli-Robson chart in LogMAR over time through Month 60</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in visual function as measured by contrast sensitivity</measure>
    <time_frame>Day 0 - Month 60</time_frame>
    <description>Change from baseline in visual function as measured by contrast sensitivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of bilateral treatment with AAV5-RPGR as measured by: Number of participants with ocular and non-ocular adverse events</measure>
    <time_frame>Day 0 - Month 60</time_frame>
    <description>Number of participants with ocular and non-ocular adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of bilateral treatment with AAV5-RPGR as measured by: Number of participants with abnormalities in Hematologic and Clinical Chemistry parameters</measure>
    <time_frame>Day 0 - Month 60</time_frame>
    <description>Number of participants with abnormalities in Hematologic and Clinical Chemistry parameters</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>X-Linked Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Deferred treatment from MGT-RPGR-021 4e11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferred treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Already treated in MGT-RPGR-021</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Already treated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferred treatment from MGT-RPGR-021 2e11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferred treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Genetic: AAV5-RPGR 4e11</intervention_name>
    <description>Bilateral, subretinal administration of AAV5-RPGR - deferred treatment group</description>
    <arm_group_label>Already treated in MGT-RPGR-021</arm_group_label>
    <arm_group_label>Deferred treatment from MGT-RPGR-021 4e11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Genetic: AAV5-RPGR 2e11</intervention_name>
    <description>Bilateral, subretinal administration of AAV5-RPGR - deferred treatment group</description>
    <arm_group_label>Already treated in MGT-RPGR-021</arm_group_label>
    <arm_group_label>Deferred treatment from MGT-RPGR-021 2e11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 3 years of age or older, has XLRP confirmed by a retinal specialist&#xD;
             and has a predicted disease-causing sequence variant in RPGR confirmed by an&#xD;
             accredited laboratory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John L Whiteford, MBA</last_name>
    <phone>+44 (0)20 3866 4320</phone>
    <email>john.whiteford@meiragtx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Bakobaki</last_name>
    <phone>+44 (0)20 3725 2349</phone>
    <email>julie.bakobaki@meiragtx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aaron L Nagiel, MD, PhD</last_name>
      <phone>323-361-7194</phone>
      <email>anagiel@chla.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Hiliary Schwartz</last_name>
      <phone>323-361-1004</phone>
      <email>hschwartz@chla.usc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vitreo Retinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Kay, MD</last_name>
      <phone>352-371-2800</phone>
      <email>christine@vra-pa.com</email>
    </contact>
    <contact_backup>
      <last_name>Jing Zang, MD</last_name>
      <phone>3526656672</phone>
      <email>JingZhang@vra-pa.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Emory Eye Centre</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nieraj E Jain, MD</last_name>
      <phone>404-778-5816</phone>
      <email>nieraj.jain@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tyler Mullen</last_name>
      <email>MULLENT@ccf.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Boston Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Huckfeldt, MD</last_name>
      <phone>617-573-6905</phone>
      <email>Rachel_Huckfeldt@meei.Harvard.Edu</email>
    </contact>
    <contact_backup>
      <last_name>Mirjana Nordmann, PhD</last_name>
      <phone>617-573-6060</phone>
      <email>Mirjana_Nordmann@MEEI.HARVARD.EDU@MEEI.HARVARD.EDU</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Univeristy of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cagri Besirli, MD</last_name>
      <phone>734-763-5874</phone>
      <email>cbesirli@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linsay Godsey</last_name>
      <phone>734-936-9798</phone>
      <email>godsey@med.umich.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Houston</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown, MD</last_name>
      <phone>713-524-3434</phone>
      <email>dmbmd@houstonretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Chelsey Moore</last_name>
      <phone>713-394-7575</phone>
      <email>chelsey.moore@houstonretina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

